| CAS NO: | 1217667-10-1 |
| 包装 | 价格(元) |
| 500 μg | 电议 |
| 1mg | 电议 |
| Cas No. | 1217667-10-1 |
| Canonical SMILES | CC1=CC=CC(C)=C1NC([C@H]2N(C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])CCCC2)=O.Cl |
| 分子式 | C17H19D7N2O.HCl |
| 分子量 | 317.9 |
| 溶解度 | Methanol: soluble,Water: soluble |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | (-)-Ropivacaine-d7is intended for use as an internal standard for the quantification of (-)-ropivacaine by GC- or LC-MS. (-)-Ropivacaine is a potent and reversible blocker of sodium channels in nerve fibers.1In vivo, (-)-ropivacaine induces complete impairment of proprioception, motor function, and nociception in the hindleg of rats when 100 μL of an 8 mM solution is injected percutaneously into the sciatic nerve.2(-)-Ropivacaine depresses myocardial contractile force in isolated rat hearts less potently than (±)-ropivacaine, as well as (-)- and (±)-bupivacaine .3Formulations containing (-)-ropivacaine have been used as local anesthetics during surgery and childbirth. 1.Hansen, T.G.Ropivacaine: A pharmacological reviewExp. Rev. Neurother.4(5)781-791(2004) 2.Sinnott, C.J., and Strichartz, G.R.Levobupivacaine versus ropivacaine for sciatic nerve block in the ratReg. Anesth. Pain Med.28(4)294-303(2003) 3.Pinotti, M.F., Hepner, A., Campos, D.H., et al.Myocardial contractility impairment with racemic bupivacaine, non-racemic bupivacaine and ropivacaine. A comparative studyActa Cir. Bras.30(7)484-490(2015) |
m.cnreagent.com